A systematic review of economic evaluations of therapy in asthma

References

• McFaddenERBronchial asthmaIsselbacherKJBraunwaldEWilsonJDMartinJBFausiASKasperDLHarrison’s Principles of Internal Medicine213th edNew York, NYMcCraw Hill19941167
   Google Scholar
• BramanSSThe global burden of asthmaChest20061304S12S16840363
   PubMed Web of Science ®Google Scholar
• SullivanSElixhauserABuistSANational Asthma Education and Prevention Program working group report on the cost effectiveness of asthma careAm J Respir Crit Care Med1996154584595
   Web of Science ®Google Scholar
• DrummondMFJeffersonTOGuidelines for authors and peer reviewers of economic submissions to the BMJ. The BMJ Economic Evaluation Working PartyBMJ199631370522752838704542
   PubMed Web of Science ®Google Scholar
• KhanKSTer RietGGlanvilleJUndertaking systematic reviews of research on effectiveness: CRD’s guidance for those carrying out or commissioning reviewsYorkNHS Centre for Reviews and Dissemination2001 [Accessed May 15, 2009] Available from: www.york.ac.uk/inst/crd/pdf/crdreport4_complete.pdf
   Google Scholar
• AnderssonFStahlEBarnesPJMollerCArhedenLAdding formoterol to budesonide in moderate asthma-health economic results from the FACET studyRespir Med20019550551211421509
   PubMed Web of Science ®Google Scholar
• AnderssonFKjellmanMForsbergGComparison of the cost-effectiveness of budesonide and sodium cromoglycate in the management of childhood asthma in everyday clinical practiceAnn Allergy Asthma Immunol200186553754411379805
   PubMed Web of Science ®Google Scholar
• BruggenjurgenBSelimDKardosPEconomic assessment of adjustable maintenance treatment with budesonide/formoterol in a single inhaler versus fixed treatment in asthmaPharmacoeconomics20052372373115987228
   PubMed Web of Science ®Google Scholar
• BuxtonMJSullivanSDAnderssonLFCountry-specific cost-effectiveness of early intervention with budesonide in mild asthmaEur Respir J200424456857415459134
   PubMed Web of Science ®Google Scholar
• CampbellLMSimpsonRJTurbittMLRichardsonPDIA comparison of the cost-effectiveness of budesonide 400 mug/day and 800 mug/day in the management of mild-to-moderate asthma in general practiceBr J Med Econ199366774
   Google Scholar
• ConnettGJLenneyWMcConchieSMThe cost-effectiveness of budesonide in severe asthmatics aged one to three yearsBr J Med Econ19936127134
   Google Scholar
• EricssonKBantjeTAHuberRMBorgSBatemanEDCost-effectiveness analysis of budesonide/formoterol compared with fluticasone in moderate-persistent asthmaRespir Med2006100458659416274980
   PubMed Web of Science ®Google Scholar
• JohanssonGAndreassonEBLarssonPEVogelmeierCFCost-effectiveness of budesonide/formoterol for maintenance and reliever therapy versus salmeterol/fluticasone plus salbutamol in the treatment of asthmaPharmacoeconomics200624769570816802845
   PubMed Web of Science ®Google Scholar
• JonssonBBerggrenFSvenssonKO’ByrnePMAn economic evaluation of combination treatment with budesonide and formoterol in patients with mild-to-moderate persistent asthmaRespir Med200498111146115415526817
   PubMed Web of Science ®Google Scholar
• LundbackBJenkinsCPriceMJThwaitesRMCost-effectiveness of salmeterol/fluticasone propionate combination product 50/250 microg twice daily and budesonide 800 microg twice daily in the treatment of adults and adolescents with asthma. International Study GroupRespir Med200094772473210926346
   PubMed Web of Science ®Google Scholar
• LundborgMWilleSBjermerLMaintenance plus reliever budesonide/formoterol compared with a higher maintenance dose of budesonide/formoterol plus formoterol as reliever in asthma: An efficacy and cost-effectiveness studyCurr Med Res Opin200622580982116709303
   PubMed Web of Science ®Google Scholar
• MaloneDCLuskinATHydrofluoroalkane-134a beclomethasone as a dominant economic asthma therapyRespir Med200397121269127614682406
   PubMed Web of Science ®Google Scholar
• MiyamotoTFujinoSNakajimaSTollemarULiljasBCost-effectiveness of budesonide Turbuhaler in the treatment of mild-to-moderate asthma in JapanAllergol Int1999484275285
   Google Scholar
• O’ByrnePCuddyLTaylorDWBirchSMorrisJSyrotuikJEfficacy and cost -benefit of inhaled corticosteroids in patients considered to have mild asthma in primary care practiceCan Respir J199633169175
   Google Scholar
• RosenhallLBorgSAnderssonFEricssonKBudesonide/formoterol in a single inhaler (Symbicort) reduces healthcare costs compared with separate inhalers in the treatment of asthma over 12 monthsInt J Clin Pract200357866266714627174
   PubMed Web of Science ®Google Scholar
• SullivanSDBuxtonMAnderssonLFCost-effectiveness analysis of early intervention with budesonide in mild persistent asthmaJ Allergy Clin Immunol20031121229113614657888
   PubMed Web of Science ®Google Scholar
• WeissKBuxtonMAnderssonFLLammCJLiljasBSullivanSDCost-effectiveness of early intervention with once-daily budesonide in children with mild persistent asthma: Results from the START studyPediatr Allergy Immunol200617212716573705
   PubMed Web of Science ®Google Scholar
• BisgaardHPriceMJMadenCOlsenNACost-effectiveness of fluticasone propionate administered via metered-dose inhaler plus babyhaler spacer in the treatment of asthma in preschool-aged childrenChest200112061835184211742910
   PubMed Web of Science ®Google Scholar
• BoothPCCapseyLJLangdonCGWellsNEJA comparison of the cost-effectiveness in alternative prophylactic therapies in the treatment of adult asthmaBr J Med Econ199586572
   Google Scholar
• O’ReillyJFWeirDCBanhamSBasranGSBoydGPatelKRIs high-dose fluticasone propionate via a metered-dose inhaler and Volumatic as efficacious as nebulized budesonide in adult asthmatics?Respir Med19989211111179519234
   PubMed Web of Science ®Google Scholar
• SteinmetzKOVolmerTTrautmannMKielhornACost-effectiveness of fluticasone and budesonide in patients with moderate asthmaClin Drug Investig1998162117123
   Web of Science ®Google Scholar
• VenablesTLMcConchieSFollowRA comparison of the cost-effectiveness of budesonide and Fluticasone dry-powder devices in the management of adult asthmaBr J Med Econ199610315323
   Google Scholar
• WilliamsJRichardsKAEase of handling and clinical efficacy of fluticasone propionate Accuhaler/Diskus inhaler compared with the Turbohaler inhaler in paediatric patients. UK Study GroupBr J Clin Pract19975131471539293055
   PubMedGoogle Scholar
• VolmerTKielhornAWeberHHWiessmannKJCost-effectiveness of fluticasone propionate and flunisolide in the treatment of corticosteroid-naive patients with moderate asthmaPharmacoeconomics19991652553110662477
   PubMed Web of Science ®Google Scholar
• StanfordRHEdwardsLDRickardKACost effectiveness of inhaled fluticasone propionate vs inhaled triamcinolone acetonide in the treatment of persistent asthmaClin Drug Investig2000204237244
   Web of Science ®Google Scholar
• CampbellLMBerggrenFEmmasCThe cost effectiveness of eformoterol via Turbohaler and salmeterol via pressurised metered dose inhaler and metered dose powder inhaler in mild to moderate asthmaJ Med Econ200034960
   Google Scholar
• LindgrenBSearsMRCampbellMCost-effectiveness of formoterol and salbutamol as asthma reliever medication in Sweden and in SpainInt J Clin Pract2005591626815707467
   PubMed Web of Science ®Google Scholar
• BerggrenFEkströmTA cost-effectiveness study comparing the as-needed use of formoterol (Oxis) and terbutaline (Bricanyl) in patients with moderate to severe asthmaRespir Med200195975375811575897
   PubMed Web of Science ®Google Scholar
• SculpherMJBuxtonMJThe episode-free day as a composite measure of effectiveness: an illustrative economic evaluation of formoterol versus salbutamol in asthma therapyPharmacoeconomics19934534535210146873
   PubMed Web of Science ®Google Scholar
• EverdenPLloydAHutchinsonJPlumbJCost-effectiveness of eformoterol Turbohaler versus salmeterol Accuhaler in children with symptomatic asthmaRespir Med200296425025812000004
   PubMed Web of Science ®Google Scholar
• Rutten-van MölkenMPvan DoorslaerEKTillMDCost-effectiveness analysis of formoterol versus salmeterol in patients with asthmaPharmacoeconomics199814667168410346418
   PubMed Web of Science ®Google Scholar
• Rutten-van MölkenMPvan DoorslaerEKJansenMCvan Essen-ZandvlietEERuttenFFCost-effectiveness of inhaled corticosteroid plus bronchodilator therapy versus bronchodilator monotherapy in children with asthmaPharmacoeconomics19934425727010146915
   PubMed Web of Science ®Google Scholar
• JohanssonGPriceMJSondhiSCost-effectiveness analysis of salmeterol/fluticasone propionate 50/100[micro]g vs fluticasone propionate 100[micro]g in adults and adolescents with asthma III: ResultsPharmacoeconomics1999161521
   Web of Science ®Google Scholar
• PalmqvisMPriceMJSondhiSCost-effectiveness analysis of salmeterol/fluticasone propionate 50/250 [micro]g vs fluticasone propionate 250[micro]g in adults and adolescents with asthma IV: ResultsPharmacoeconomics1999162328
   Web of Science ®Google Scholar
• PietersWRLundbackBSondhiSPriceMJThwaitesRMACost-Effectiveness Analysis of Salmeterol/Fluticasone Propionate 50/500[micro]g vs Fluticasone Propionate 500[micro]g in Patients with Corticosteroid-Dependent Asthma V: ResultsPharmacoeconomics1999162934
   Web of Science ®Google Scholar
• PriceMJBriggsAHDevelopment of an economic model to assess the cost-effectiveness of asthma management strategiesPharmacoeconomics200220318319411929348
   PubMed Web of Science ®Google Scholar
• O’ConnorRDNelsonHBorkerRCost-effectiveness of fluticasone propionate plus salmeterol versus fluticasone propionate plus montelukast in the treatment of persistent asthmaPharmacoeconomics2004221281582515294013
   PubMed Web of Science ®Google Scholar
• PietersWRWilsonKKSmithHCTammingaJJSondhiSSalmeterol/fluticasone propionate versus fluticasone propionate plus montelukast: a cost-effective comparison for asthmaTreat Respir Med20054212913815813665
   PubMedGoogle Scholar
• O’ConnorRDStanfordRCrimCEffect of fluticasone propionate and salmeterol in a single device, fluticasone propionate, and montelukast on overall asthma control, exacerbations, and costsAnn Allergy Asthma Immunol200493658158815609769
   PubMed Web of Science ®Google Scholar
• MenendezRStanfordRHEdwardsLKalbergCRickardKCost-efficacy analysis of fluticasone propionate versus zafirlukast in patients with persistent asthmaPharmacoeconomics200119886587411596838
   PubMed Web of Science ®Google Scholar
• BorkerREmmettAJhingranPRickardKDorinskyPDetermining economic feasibility of fluticasone propionate-salmeterol vs montelukast in the treatment of persistent asthma using a net benefit approach and cost-effectiveness acceptability curvesAnn Allergy Asthma Immunol200595218118916136769
   PubMed Web of Science ®Google Scholar
• ShethKBorkerREmmettARickardKDorinskyPCost-effectiveness comparison of salmeterol/fluticasone propionate versus montelukast in the treatment of adults with persistent asthmaPharmacoeconomics2002201390991812381242
   PubMed Web of Science ®Google Scholar
• BrownRTurkFDalePBousquetJCost-effectiveness of omalizumab in patients with severe persistent allergic asthmaAllergy200762214915317298423
   PubMed Web of Science ®Google Scholar
• DewildeSTurkFTambourMSandstromTThe economic value of anti-IgE in severe persistent, IgE-mediated (allergic) asthma patients: adaptation of Innovate to SwedenCurr Med Res Opin20062291765177616968580
   PubMed Web of Science ®Google Scholar
• BoothPCWellsNEMorrisonAKA comparison of the cost effectiveness of alternative prophylactic therapies in childhood asthmaPharmacoeconomics199610326226810163573
   PubMed Web of Science ®Google Scholar
• MainCShepherdJAndersonRSystematic review and economic analysis of the comparative effectiveness of different inhaled corticosteroids and their usage with long-acting beta2 agonists for the treatment of chronic asthma in children under the age of 12 yearsHealth Technol Assess200812201174 iii–iv.18485272
   PubMed Web of Science ®Google Scholar